GTx's CEO Discusses Q2 2012 Results - Earnings Call Transcript

GTx, Inc. (GTXI)

Q2 2012 Earnings Call

August 8, 2012; 09:00 am ET


Dr. Mitchell Steiner - Chief Executive Officer

Marc Hanover - President & Chief Operating Officer


Joel Sendek - Stifel Nicolaus

David Nierengarten - Wedbush Securities

Biren Amin - Jefferies

Ryan Martin - Lazard Capital Markets

Howard Liang - Leerink Swann



Good day ladies and gentlemen and welcome to the GTx Inc corporate update and second quarter 2012 financial results conference call. My name is Tahisha and I will be your operator for today.

At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. (Operator Instructions).

I would now like to turn the conference over to your host for today, Dr. Mitchell Steiner, CEO of GTx, please proceed.

Dr. Mitchell Steiner

Thank you operator. I will be making forward-looking comments during today’s call and I direct you to the press release of our financial results we filed today and the Quarterly Report on Form 10-Q we filed May 10, 2012 with the SEC, where we discuss the risks and uncertainties that affect our business.

GTx has made good progress in advancing our two late stage clinical programs, enobosarm for the prevention and treatment of muscle wasting in patients who have advanced non-small cell lung cancer and Capesaris as a secondary hormonal therapy in men with castration resistant prostate cancer.

As with the Enobosarm program, we are currently enrolling subjects into two international pivotal Phase III clinical trials called POWER 1 and POWER 2 in over 80 clinical sites located in the United States, Europe and South America.

If you liked this article you might like

XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny

3 Stocks Under $10 to Trade for Big Breakouts

4 Biotech Stocks Under $10 to Watch for Breakout Trades

5 Stocks Under $10 Set to Soar

5 Stocks Ready for Breakouts